medac is a pharmaceutical company which has specialized in the treatment of malignant diseases since it was founded in 1970. Many years of experience makes medac one of the leading manufacturers of oncology products in Germany and in international markets. medac also offers new and well proven therapeutic options in the fields of urology, autoimmune diseases and fibrinolysis.
More over, medac is one of the few companies engaged also in the field of diagnostics.
medac is constantly broadening their portfolio of products to allow the consistent provision of high quality preparations.
Oncology department of medac has four specialized units and its line of products, covers virtually the entire area of solid tumor therapy.
Besides providing the treatment itself, medac is working on therapies for improving peoples quality of life of patients.
medac conducts research in corporation with academic institutions as well as pharmaceutical or biotech companies.
medac is always interested in expanding their portfolio of products in the various fields which also includes supportive care and basic therapeutics. medac is interested in adding value to well known preparations in order to serve the needs and requirements of the markets.
Beijing SL Pharmaceutical Co., Ltd, well known as “SL PHARMA”, is a high biotechnology pharmaceutical company, mainly engaged in developing and marketing gene engineering drugs. The company founded in December 1994, was originally as the name “Beijing Bailuyuan Biopharmaceutical Co., Ltd”, and changed the name as “Beijing SL Pharmaceutical Co., Ltd.” in 1998. It became a Joint-stock Company Limited in August 2000 and was listed in Chinese Stock Exchange in 2004.
SL Pharma is located in Haidian District, Beijing, China. Registration capital of the company is CNY 82 million, and net asset is about CNY 150 million. The plant is located in Beijing Badachu High-tech Zone, which occupies 12,000 square meters, and workshops are well equipped with GMP authenticate production lines. Annual production capacity of the manufacturers reaches 20 millions of pharmaceutical injections, and 200 millions of oral solid pharmaceutical products (tablets). All products have GMP Authentication issued by Chinese State Food and Drug Administration (SFDA). Management is performed according to the requirement of international GMP standards from workshops, equipments, raw or auxiliary materials, packing materials to production, quality and hygiene.
SL Pharma has obtained four grants supported by “National 863 Item” since 1997. It was authenticated as High Biotechnology Enterprise by Beijing Science and Technology Committee in October 1996 and was ranked as Beijing Leading Biotech Enterprise by both National Ministry of Science and Technology and Chinese Academy of Science. In December 2001, R&D system was certificated as National Postdoctoral Workstation and Beijing city’s technical center.
DONGKOOK Pharmaceutical Co. Ltd. was established in October 1968 as UEC & Co. Ltd later changed its name to DONGKOOK Pharmaceutical Co. Ltd in March 1982.
Since its establishment in 1968, DONGKOOK Pharmaceutical Co. Ltd. has consolidated its conditions for existence as a pharmaceutical company through ceaseless study of its products and development of manpower.
Development & marketing of innovative cancer therapies is the priority of DONGKOOK Pharmaceutical Co. Ltd.
DONGKOOK invests more then 5% of the annual sale for research and development.
In 1992, DONGKOOK Pharmaceutical Co. Ltd. developed the prefilled syringe system in its second factory for the first time in Asia and produced a large amount of various kinds of ultra modern injection agents. Located on its site are its central research institute, raw material factory, etc. where the raw material of its main products are extracted and synthesized directly.
DONGKOOK has been concentrating R&D and technical innovation since its establishment in 1968. Since1968, DONGKOOK’s active R&D Center has been not only working toward the development of new drugs but also studying in collaboration with local universities and foreign research centers.
Synchrony Pharma is a rapidly expanding specialty pharmaceutical company with a clear vision of providing consistently high quality, lower cost alternatives to proprietary medications to its customers. Our aim is to improve the affordability of care for patients and the financial strength of the global healthcare system. Synchrony Pharma specialises in the development and commercialisation of generic pharmaceutical products. Our product portfolio focus is to deliver both unmet generic need, and, to target the development of future patent expiring molecules. This product portfolio, combined with our business model, is geared towards serving the hospital sector. Through our operations in the UK and Ireland we provide high quality and affordable products to patients, with a geographical reach, which extends across Europe through numerous successful partnerships. The company is led by a strong management team, which prides itself on “making a difference” within the Healthcare sector, through the development of a fast and reliable service, and, constantly striving to be the “partner of choice” for our customers.
The TECNIMEDE GROUP is a private group of pharmaceutical companies that started its activity in 1980.
Its activity is focused on the development and marketing of medicinal products for human use, being its mission to contribute for the improvement of health and access to medicinal products worldwide.
The Tecnimede Group’s strategy is based on a strong investment in Research & Development activities, whose results obtained will allow the consolidation of the Group’s position in its markets and its internationalization.
To achieve its objectives, the Group invested in the construction of a Research & Development Centre – Laborqualitas – and in the acquisition of 2 production units – West Pharma and Atlantic Pharma.
Currently, the Group has three commercial lines in Portugal – Tecnimede, Pentafarma and Farmoz, one in Spain -Tecnimede España and another in Morocco -Tecnimede Maroc.
As a result of the strategy assumed, the Tecnimede Group is regularly distinguished by the Portuguese Governmental institutions by the investment of significant economical resources in R&D activities.
Currently, with a portfolio of over 75 products developed in Laborqualitas, the Tecnimede Group manages over 2,000 MAs at a global level, being present, either directly or through partnerships, in almost all countries of the European Union, as well as in several countries of North Africa, Asia, Middle East and North America.